Leerink Partners Initiates Coverage On Quince Therapeutics with Outperform Rating, Announces Price Target of $4

Benzinga Newsdesk www.benzinga.com Positive 80.5%

Neg 0% Neu 0% Pos 80.5%

Leerink Partners analyst Joseph Schwartz initiates coverage on Quince Therapeutics (NASDAQ:QNCX) with a Outperform rating and announces Price Target of $4.